The World Health Organization (WHO) has published new HIV prevention guidelines titled “Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis.”
WHO called lenacapavir (LEN) “a transformative step forward in protecting people at risk of HIV – particularly those who face challenges with daily adherence, stigma, or access to healthcare” in an announcement. Additionally, WHO outlines their testing recommendations in the document: rapid diagnostic tests for those using long-acting injectable PrEP.
LEN is injected twice a year for the prevention of HIV. WHO hopes their decision to recommend LEN will help broaden accessibility to HIV prevention.
